Pelthos Therapeutics Inc. (PTH) - Form 8-K Summary
Business Context and Reporting Period
Date of Report: November 7, 2025 (Event Date: November 6, 2025)
Company: Pelthos Therapeutics Inc., a Nevada corporation and emerging growth company.
Primary Event: The Company closed a $18.0 million senior secured convertible note financing and simultaneously acquired the assets of Xepi (ozenoxacin) cream from Biofrontera Inc.
Key Financial Metrics and Transaction Details
- Financing Proceeds: Approximately $18.0 million in gross proceeds from the sale of senior secured convertible notes.
- Debt Instrument: Senior secured convertible notes with an original principal of $18.0 million.
- Interest Rate: 8.5% per annum (increases to 18.0% upon default).
- Maturity Date: November 6, 2027.
- Conversion Price: $34.442 per share (subject to automatic reduction to $29.73 under specific conditions).
- Acquisition Cost (Xepi): Aggregate purchase price not to exceed $10.0 million, consisting of:
- $3.0 million cash payment at closing.
- $1.0 million cash payment upon availability of commercial quantities.
- Up to $6.0 million in contingent milestone payments based on net sales achievements.
- Liquidity Impact: The filing does not provide pre-transaction cash balances or post-transaction liquidity metrics.
Material Changes and Agreements
The filing details several material definitive agreements entered into on November 6, 2025:
- Convertible Note Financing: Investors include Ligand Pharmaceuticals Incorporated. Notes are secured by a lien on 10.0% of net sales of Xepi (accrued as 5.0% liability until default) and royalty payments from Sato Pharmaceutical Co., Ltd. regarding ZELSUVMI.
- Asset Acquisition: Acquisition of Xepi assets, including IP, manufacturing rights, and regulatory filings, from Biofrontera Inc.
- Supply Agreement: Exclusive license and API supply agreement with Ferrer Internacional, S.A. and Interquim, S.A.U. for Xepi in the U.S. territory. The Company is required to purchase 100% of Xepi requirements from Interquim.
- Royalty Adjustments: Investors received a 5.0% royalty on net sales of Xepi and rights to Sato payments. The Company amended prior royalty agreements to exclude Nitricil and Xepi from certain royalty sales to third parties.
- Lock-Up Agreements: Amended and restated lock-up agreements with Ligand and other investors extending restrictions on share sales until December 31, 2025.
Guidance, Risks, and Contingencies
- Forward-Looking Statements: The Company issued a press release containing forward-looking statements regarding the financing and Xepi transactions, subject to risks and uncertainties.
- Default Provisions: Events of default include failure to issue conversion shares, delisting, insolvency, or failure to pay principal/interest. Upon default, holders may redeem notes at 115% of the conversion amount or the greater of the conversion value.
- Change of Control: Holders may require redemption at 125% of the conversion amount or the greater of the conversion value in the event of a change of control.
- Shareholder Approval: The Company must seek shareholder approval to reduce the conversion price below $34.442 per share.
- Registration Rights: The Company must file a resale registration statement within 60 days of closing and use best efforts to have it declared effective within 90 days.
Investor Verification Checklist
- Verify the exact amount of transaction expenses deducted from the $18.0 million gross proceeds to determine net cash received.
- Confirm the current cash position and working capital of the Company post-closing to assess runway.
- Review the specific definitions of "Net Sales" for Xepi to understand the trigger points for the $6.0 million in contingent milestone payments.
- Assess the impact of the 5.0% royalty obligation on future Xepi profitability.
- Monitor the timeline for the filing and effectiveness of the resale registration statement for the convertible notes.
- Verify the status of the shareholder approval process regarding the potential conversion price adjustment.